Monitoring the electrophysiological effects of hydroquinidine non-invasively in patients with Brugada syndrome

27 August 2023 (10:15 - 11:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Julia Clair Isbister

Garvan Institute of Medical Research, Sydney (Australia)

7 More presentations in this session

Presentation thumbnail

An online international survey study into the incidence and potential reasons of therapy non-adherence in catecholaminergic polymorphic ventricular tachycardia: preliminary results

Mrs P. Peltenburg (Amsterdam, NL)

Abstract Slides Video

Presentation thumbnail

Roles of atrial arrhythmias in triggering torsade de pointes in patients with acquired long QT syndrome

Doctor R. Tochibora (Gifu, JP)

Abstract Slides Video

Presentation thumbnail

Prevalence and prognostic value of epilepsy and Brugada syndrome

Miss E. Rossetto (Milan, IT)

Abstract Slides Video

Presentation thumbnail

Characterization of the cardiac and non-cardiac phenotype associated with genetic variants in KCNJ2

Doctor D. Abrams (Boston, US)

Abstract Slides Video

Presentation thumbnail

Interpretable machine learning model using Extreme Gradient Boosting with Nonnegative Matrix Factorization improves the accuracy of arrhythmic risk prediction in Brugada Syndrome

Professor G. Tse (Hong Kong, CN)

Abstract Slides

Access the full session

Session thumbnail

Ion channel diseases: risk stratification and treatment

The Event

Event poster

ESC Congress 2023

27 August 2023 10:15 CET

You may be interested in

Congress Presentation

Long-term performance of different treatment approaches in Brugada Syndrome

Congress Presentation

Why, when, and for whom should we use quinidine?

Congress Presentation

Artemisinin combined with low dose quinidine suppresses ventricular tachyarrhythmia in a model of Brugada syndrome

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources